-
Subject Areas on Research
-
Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species.
-
Antifungal resistance: the clinical front.
-
Aspergillus niger: an unusual cause of invasive pulmonary aspergillosis.
-
Blastomycosis.
-
Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole.
-
Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
-
Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
-
Case 215: voriconazole-induced periostitis.
-
Caspofungin for the treatment of azole resistant candidemia in a premature infant.
-
Cerebral phaeohyphomycosis in an immunodeficient child treated medically with combination antifungal therapy.
-
Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole.
-
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.
-
Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants.
-
Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets.
-
Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.
-
Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.
-
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
-
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.
-
Delayed recalcitrant fungal endophthalmitis secondary to Curvularia.
-
Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation.
-
Epidemiological and mycological characteristics of candidemia in patients with hematological malignancies attending a tertiary-care center in India.
-
Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients.
-
Improved outcome in central nervous system aspergillosis, using voriconazole treatment.
-
In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3.
-
In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.
-
In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus.
-
Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases.
-
Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome.
-
Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
-
Invasive Curvularia Infection in Pediatric Patients With Hematologic Malignancy Identified by Fungal Sequencing.
-
Old and new: appropriate dosing for neonatal antifungal drugs in the nursery.
-
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.
-
Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.
-
Polyhexamethylene biguanide and calcineurin inhibitors as novel antifungal treatments for Aspergillus keratitis.
-
Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole.
-
Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone.
-
Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia.
-
Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes.
-
Scanning Quadrupole Data-Independent Acquisition, Part B: Application to the Analysis of the Calcineurin-Interacting Proteins during Treatment of Aspergillus fumigatus with Azole and Echinocandin Antifungal Drugs.
-
Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide.
-
Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.
-
Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.
-
Use of newer antifungal therapies in clinical practice: what do the data tell us?
-
Utility of CT assessment in hematology patients with invasive aspergillosis: a post-hoc analysis of phase 3 data.
-
Voriconazole Treatment for an Infant With Intractable Candida glabrata Meningitis.
-
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
-
Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.
-
Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.
-
Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008-2019.
-
Voriconazole treatment for less-common, emerging, or refractory fungal infections.